DeepMed Research

University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Addressing Social Vulnerabilities in Cardiovascular Disease

Not Applicable

Conditions: Acute Myocardial Infarction
Ischemic Heart Disease
Coronary Artery Disease
Congestive Heart Failure

Interventions: Other: Socially Enhanced Transitional Care Intervention

First Posted Date: 2018-08-02

Last Posted Date: 2021-06-08

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 50

Registration Number: NCT03613064

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

Completed

Conditions: Hemoglobinopathies
Nonmalignant Diseases
Immunodeficiencies
Sickle Cell Disease
Hematologic Malignancies
Genetic Inborn Errors of Metabolism
Thalassemia
Fanconi's Anemia

Interventions: Drug: Clofarabine
Drug: Fludarabine Injection

First Posted Date: 2018-08-01

Last Posted Date: 2021-10-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 30

Registration Number: NCT03609814

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed

Conditions: Immune Deficiency
Thalassemia
Hemoglobinopathies
Fanconi Anemia
Sickle Cell Disease
Nonmalignant Diseases
Hematologic Malignancies
Genetic Inborn Errors of Metabolism

Interventions: Drug: Thiotepa

First Posted Date: 2018-08-01

Last Posted Date: 2023-09-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT03609840

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed

Conditions: Hematologic Malignancies
Thalassemia
Hemoglobinopathies
Fanconi's Anemia
Nonmalignant Diseases
Immunodeficiencies
Genetic Inborn Errors of Metabolism
Sickle Cell Disease

Interventions: Drug: Melphalan

First Posted Date: 2018-08-01

Last Posted Date: 2021-10-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT03609827

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Evaluating the Impact of the National Health Insurance Scheme of Ghana on Surgical Care

Completed

Conditions: General Surgery, Costs and Cost Analysis

First Posted Date: 2018-07-27

Last Posted Date: 2018-07-27

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 203

Registration Number: NCT03604458

Locations: 🇬🇭
Korle-Bu Teaching Hospital, Accra, Ghana

Impact of a Lower Extremity Amputation Pathway Protocol in Dysvascular Patients

Not Applicable

Completed

Conditions: Lower Extremity Amputation

Interventions: Other: Lower Extremity Amputation Pathway

First Posted Date: 2018-07-19

Last Posted Date: 2021-02-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 11

Registration Number: NCT03592316

Locations: 🇺🇸
Community Regional Medical Center, Fresno, California, United States

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

Phase 1

Completed

Conditions: Iliac Artery Disease
Claudication, Intermittent
PAD
Peripheral Arterial Disease
Claudication
SFA - Superficial Femoral Artery Stenosis
Vascular Calcification

Interventions: Drug: 18F-FDG

First Posted Date: 2018-07-18

Last Posted Date: 2020-11-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 9

Registration Number: NCT03590769

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
San Francisco General Hospital, San Francisco, California, United States

mHealth App for Engagement in Care Among Youth Living With HIV

Not Applicable

Completed

Conditions: HIV/AIDS
Young Adults
Mobile Health

Interventions: Other: Mobile Health Application

First Posted Date: 2018-07-16

Last Posted Date: 2022-07-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 83

Registration Number: NCT03587857

Locations: 🇺🇸
University of California San Francisco, Mission Bay Campus, San Francisco, California, United States

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

Phase 2

Completed

Conditions: Cytomegalovirus Anterior Uveitis

Interventions: Drug: Valganciclovir Hydrochloride
Drug: Ganciclovir Sodium
Drug: Placebo Oral Tablet
Drug: Topical placebo

First Posted Date: 2018-07-13

Last Posted Date: 2024-12-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 51

Registration Number: NCT03586284

Locations: 🇺🇸
Proctor Foundation, UCSF, San Francisco, California, United States
🇹🇭
Chulalongkorn University, Bangkok, Thailand
🇹🇭
Chiang Mai University, Chiang Mai, Thailand

and more 1 locations

Remote Dielectric Sensing (ReDS) Assisted Diuresis in Acute Decompensated Heart Failure

Not Applicable

Recruiting

Conditions: Heart Failure; With Decompensation

Interventions: Device: ReDS-Guided
Device: Usual Care

First Posted Date: 2018-07-13

Last Posted Date: 2022-12-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 100

Registration Number: NCT03586336

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy